Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 23, 2021

Tisagenlecleucel Is Not Superior to Salvage Therapy in B-Cell Lymphoma

The New England Journal of Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
N. Engl. J. Med 2021 Dec 14;[EPub Ahead of Print], MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, A Sureda, R Greil, C Thieblemont, F Morschhauser, M Janz, I Flinn, W Rabitsch, YL Kwong, MJ Kersten, MC Minnema, H Holte, EHL Chan, J Martinez-Lopez, AMS Müller, RT Maziarz, JP McGuirk, E Bachy, S Le Gouill, M Dreyling, H Harigae, D Bond, C Andreadis, P McSweeney, M Kharfan-Dabaja, S Newsome, E Degtyarev, R Awasthi, C Del Corral, G Andreola, A Masood, SJ Schuster, U Jäger, P Borchmann, JR Westin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading